在治疗性药物的研发中，效应分子与人免疫球蛋白IgG1 Fc片段或人血清白蛋白形成的融合蛋白疗效不变，但体内半衰期明显延长、药物耐受性增加、副作用减少。在疫苗研发中，抗原分子与毒素分子或Fc形成的融合蛋白是很好的新型疫苗，并能激发细胞免疫。

 In the development of biopharmaceuticals, fusion proteins of effectors and IgG1 Fc fragment or human albumin have the same treatment efficacy as the effectors alone, much prolonged half-life, increased drug tolerance, and decreased side effects. In the studies of vaccines, the fusion proteins of antigens and toxins or IgG1 Fc will become new type of vaccines which can also stimulate T cell response.